Page last updated: 2024-12-05

salicylaldehyde isonicotinoyl hydrazone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Salicylaldehyde isonicotinoyl hydrazone (SIH) is a compound with a wide range of biological activities, particularly as an anti-cancer agent. It is synthesized through a condensation reaction between salicylaldehyde and isonicotinoyl hydrazide. SIH has shown promising results in inhibiting the growth of various cancer cells, including leukemia, breast cancer, and colon cancer. The mechanism of action is believed to involve multiple pathways, including induction of apoptosis, cell cycle arrest, and inhibition of angiogenesis. Studies have also explored its potential in treating other diseases like malaria and parasitic infections. The unique structure of SIH allows for its interaction with various biological targets, making it a subject of extensive research to understand its therapeutic potential and develop more potent and selective derivatives.'

salicylaldehyde isonicotinoyl hydrazone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10323
MeSH IDM0370334

Synonyms (10)

Synonym
CBDIVE_001657
salicylaldehyde isonicotinoyl hydrazone
dtxsid0046272 ,
HMS2231I23
FT-0632228
HMS3371L08
VBIZUNYMJSPHBH-UHFFFAOYSA-N
n-[(2-hydroxyphenyl)methylideneamino]pyridine-4-carboxamide
salinazid 100 microg/ml in acetonitrile
n'-[(2-hydroxyphenyl)methylidene]pyridine-4-carbohydrazide

Research Excerpts

Overview

Salicylaldehyde isonicotinoyl hydrazone (SIH) is a lipophilic, orally-active tridentate iron ch. It binds ferric ions from the cellular labile iron pool and is able to protect various tissues against oxidative damage.

ExcerptReferenceRelevance
"Salicylaldehyde isonicotinoyl hydrazone (SIH) is a small molecule and lipophilic chelating agent that firmly binds ferric ions from the cellular labile iron pool and is able to protect various tissues against oxidative damage. "( 2,6-Dihydroxybenzaldehyde Analogues of the Iron Chelator Salicylaldehyde Isonicotinoyl Hydrazone: Increased Hydrolytic Stability and Cytoprotective Activity against Oxidative Stress.
Jansová, H; Kubeš, J; Reimerová, P; Roh, J; Šimůnek, T; Štěrbová-Kovaříková, P, 2018
)
2.17
"Salicylaldehyde isonicotinoyl hydrazone (SIH) is a lipophilic, tridentate iron chelator with marked anti-oxidant and modest cytotoxic activity against neoplastic cells. "( Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties.
Bureš, J; Hašková, P; Hergeselová, T; Hrušková, K; Jansová, H; Jirkovská, A; Kalinowski, DS; Kolbabová, L; Kovaříková, P; Lane, DJ; Macháček, M; Potůčková, E; Pravdíková, K; Richardson, DR; Richardson, V; Šimůnek, T; Špirková, IA; Vávrová, K, 2014
)
2.11
"Salicylaldehyde isonicotinoyl hydrazone (SIH) is an intracellular iron chelator with well documented potential to protect against oxidative injury both in vitro and in vivo. "( LC-UV/MS methods for the analysis of prochelator-boronyl salicylaldehyde isonicotinoyl hydrazone (BSIH) and its active chelator salicylaldehyde isonicotinoyl hydrazone (SIH).
Bureš, J; Filipský, T; Franz, KJ; Jansová, H; Klimeš, J; Kovaříková, P; Kučera, R; Mladěnka, P; Šimůnek, T; Stariat, J; Wang, Q, 2015
)
2.1
"Salicylaldehyde isonicotinoyl hydrazone (SIH) is an iron chelator of the aroylhydrazone class that displays antioxidant or prooxidant effects in different mammalian cell lines. "( Prooxidant and antioxidant properties of salicylaldehyde isonicotinoyl hydrazone iron chelators in HepG2 cells.
Caro, AA; Commissariat, A; Desrochers, LP; Dunn, C; García, SL; Goodwin, TE; Kim, H; Smith, A; Strang, H; Stuppy, J, 2015
)
2.13
"Salicylaldehyde isonicotinoyl hydrazone (SIH) is a strong intracellular iron chelator with well documented potential to protect against oxidative damage both in vitro and in vivo."( Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products.
Bureš, J; Franz, KJ; Hašková, P; Jansová, H; Jirkovská, A; Kovaříková, P; Macháček, M; Roh, J; Šimůnek, T; Wang, Q, 2016
)
1.16
"Salicylaldehyde isonicotinoyl hydrazone (SIH) is a lipophilic, orally-active tridentate iron chelator providing both effective protection against various types of oxidative stress-induced cellular injury and anticancer action. "( Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: novel iron chelators with selective antiproliferative action.
Bendová, P; Hašková, P; Hrušková, K; Jansová, H; Kovaříková, P; Macková, E; Simůnek, T; Vávrová, A; Vávrová, K, 2012
)
2.1
"Salicylaldehyde isonicotinoyl hydrazone (SIH) is an iron-chelating aromatic hydrazone with promising pharmacological properties. "( HPLC-DAD and MS/MS analysis of novel drug candidates from the group of aromatic hydrazones revealing the presence of geometric isomers.
Hasková, P; Hrusková, K; Klimes, J; Kovaríková, P; Schöngut, M; Tomalová, K; Vávrová, K, 2008
)
1.79

Dosage Studied

ExcerptRelevanceReference
" Hence, this study points out that aroylhydrazone iron chelators can induce a significant cardioprotection against anthracycline cardiotoxicity; however, they share the curious dose-response relationship which is unrelated to the chemical structure or the route of the administration of the chelator."( Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH).
Adamcová, M; Gersl, V; Guncová, I; Kaiserová, H; Mazurová, Y; Palicka, V; Ponka, P; Popelová, O; Potácová, A; Simůnek, T; Sterba, M, 2007
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (44)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's28 (63.64)29.6817
2010's15 (34.09)24.3611
2020's1 (2.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.03 (24.57)
Research Supply Index3.81 (2.92)
Research Growth Index6.21 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other44 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]